Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Debt (2022 - 2025)

Axsome Therapeutics' Non-Current Debt history spans 4 years, with the latest figure at $117.7 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 34.84% year-over-year to $117.7 million; the TTM value through Dec 2025 reached $117.7 million, down 34.84%, while the annual FY2025 figure was $117.7 million, 34.84% down from the prior year.
  • Non-Current Debt for Q4 2025 was $117.7 million at Axsome Therapeutics, roughly flat from $117.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $181.4 million in Q1 2025 and bottomed at $49.3 million in Q1 2022.
  • The 4-year median for Non-Current Debt is $162.2 million (2023), against an average of $141.5 million.
  • The largest annual shift saw Non-Current Debt skyrocketed 199.35% in 2023 before it tumbled 34.84% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $94.3 million in 2022, then surged by 88.92% to $178.1 million in 2023, then grew by 1.48% to $180.7 million in 2024, then crashed by 34.84% to $117.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Non-Current Debt are $117.7 million (Q4 2025), $117.6 million (Q3 2025), and $117.5 million (Q2 2025).